SRD5A3
SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
Overview
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol. Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.93, genetic association 0.00, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
- 1 · What it is
SRD5A3 (Polyprenal reductase) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Prostate cancer.
- 2 · What goes wrong in cancer
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol.
- 3 · How drugs use it
No product in this corpus aims at SRD5A3 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:25812 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H8P0 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000128039 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: prostate cancer 0.59 (GraphQL API, CC0))
Biology
Plays a key role in early steps of protein N-linked glycosylation by being involved in the conversion of polyprenol into dolichol. Acts as a polyprenal reductase that mediates the reduction of polyprenal into dolichal in a NADP-dependent mechanism. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT). Location: Endoplasmic reticulum membrane (UniProt). Locus 4q12 (HGNC).
- Prostate cancer: Open Targets association 0.59 with prostate cancer (MONDO_0008315)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"SRD5A3" OR ABSTRACT:"SRD5A3" OR TITLE:"steroid 5 alpha-reductase 3" OR ABSTRACT:"steroid 5 alpha-reductase 3" OR TITLE:"Polyprenal reductase" OR ABSTRACT:"Polyprenal reductase" OR TITLE:"FLJ13352" OR ABSTRACT:"FLJ13352" OR TITLE:"SRD5A2L" OR ABSTRACT:"SRD5A2L" OR TITLE:"SRD5A2L1" OR ABSTRACT:"SRD5A2L1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SRD5A3, not a curated reading list.